Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telacebec - Qurient Co

Next Previous
Search
Drug Profile

Telacebec - Qurient Co

Alternative Names: Q-203

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qurient Co
  • Class Amides; Anti-inflammatories; Antibacterials; Antituberculars; Imidazoles; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Bacterial growth inhibitors; Electron transport complex III inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Tuberculosis
  • No development reported Buruli ulcer

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Buruli-ulcer in South Korea
  • 03 Jul 2024 Barwon Health plans the TREAT-BU phase II trial for Buruli-ulcer (PO, Tablet) in July 2024 (NCT06481163)
  • 17 May 2024 Pharmacodynamics data from a preclinical trial in Tuberculosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top